First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results D. Planchard, A. Poltoratskiy,S-W. Kim,T. M. Kim, N. Yanagitani, H. Kagamu,P-H. Feng, B. Hughes,T-Y. Yang,J. C-H. Yang, C. K. Lee, N. Karaseva, P. Mitchell, Y. Tambo, E. Armenteros Monterroso, A. Todd, A. Sahasrabudhe, P. A. Janne, K. KobayashiANNALS OF ONCOLOGY(2023)引用 0|浏览7暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要